메뉴 건너뛰기




Volumn 18, Issue SUPPL. 2, 2012, Pages 1-15

Antifungal prophylaxis in haematology patients: The role of voriconazole

Author keywords

Antifungal prophylaxis; Haematology; Leukaemia; Stem cell transplantation; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; PREDNISONE; VORICONAZOLE;

EID: 84858176195     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03772.x     Document Type: Review
Times cited : (26)

References (109)
  • 1
    • 41149123494 scopus 로고    scopus 로고
    • Risk factors for breakthrough invasive fungal infection during secondary prophylaxis
    • Cornely OA, Bohme A, Reichert D et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008; 61: 939-946.
    • (2008) J Antimicrob Chemother , vol.61 , pp. 939-946
    • Cornely, O.A.1    Bohme, A.2    Reichert, D.3
  • 2
    • 0042243672 scopus 로고    scopus 로고
    • Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
    • Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833.
    • (2003) Blood , vol.102 , pp. 827-833
    • Fukuda, T.1    Boeckh, M.2    Carter, R.A.3
  • 3
    • 63849233258 scopus 로고    scopus 로고
    • The changing face of epidemiology of invasive fungal disease in Europe
    • Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52: 197-205.
    • (2009) Mycoses , vol.52 , pp. 197-205
    • Lass-Florl, C.1
  • 4
    • 0036532203 scopus 로고    scopus 로고
    • Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients
    • Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
    • (2002) Clin Infect Dis , vol.34 , pp. 909-917
    • Marr, K.A.1    Carter, R.A.2    Crippa, F.3    Wald, A.4    Corey, L.5
  • 5
    • 0034979734 scopus 로고    scopus 로고
    • Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants
    • Ninin E, Milpied N, Moreau P et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis 2001; 33: 41-47.
    • (2001) Clin Infect Dis , vol.33 , pp. 41-47
    • Ninin, E.1    Milpied, N.2    Moreau, P.3
  • 6
    • 33846934215 scopus 로고    scopus 로고
    • Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality
    • Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
    • (2007) Clin Infect Dis , vol.44 , pp. 531-540
    • Upton, A.1    Kirby, K.A.2    Carpenter, P.3    Boeckh, M.4    Marr, K.A.5
  • 7
    • 33745797267 scopus 로고    scopus 로고
    • Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients
    • Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162: 1-15.
    • (2006) Mycopathologia , vol.162 , pp. 1-15
    • Bhatti, Z.1    Shaukat, A.2    Almyroudis, N.G.3    Segal, B.H.4
  • 8
    • 67651114113 scopus 로고    scopus 로고
    • Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges
    • Ben-Ami R, Lewis RE, Kontoyiannis DP. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 2009; 22: 376-384.
    • (2009) Curr Opin Infect Dis , vol.22 , pp. 376-384
    • Ben-Ami, R.1    Lewis, R.E.2    Kontoyiannis, D.P.3
  • 9
    • 0031010201 scopus 로고    scopus 로고
    • Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
    • Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
    • (1997) J Infect Dis , vol.175 , pp. 1459-1466
    • Wald, A.1    Leisenring, W.2    van Burik, J.A.3    Bowden, R.A.4
  • 10
    • 35348882622 scopus 로고    scopus 로고
    • Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne
    • Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-1170.
    • (2007) Clin Infect Dis , vol.45 , pp. 1161-1170
    • Pagano, L.1    Caira, M.2    Nosari, A.3
  • 11
    • 76749164890 scopus 로고    scopus 로고
    • Fungal infections in oncology patients: update on epidemiology, prevention, and treatment
    • Marr KA. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol 2010; 22: 138-142.
    • (2010) Curr Opin Oncol , vol.22 , pp. 138-142
    • Marr, K.A.1
  • 12
    • 70350107583 scopus 로고    scopus 로고
    • Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection
    • Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-4752.
    • (2009) Cancer , vol.115 , pp. 4745-4752
    • Sipsas, N.V.1    Lewis, R.E.2    Tarrand, J.3
  • 13
    • 77950280868 scopus 로고    scopus 로고
    • Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database
    • Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-1100.
    • (2010) Clin Infect Dis , vol.50 , pp. 1091-1100
    • Kontoyiannis, D.P.1    Marr, K.A.2    Park, B.J.3
  • 14
    • 58749083534 scopus 로고    scopus 로고
    • Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry
    • Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-273.
    • (2009) Clin Infect Dis , vol.48 , pp. 265-273
    • Neofytos, D.1    Horn, D.2    Anaissie, E.3
  • 15
    • 22844441134 scopus 로고    scopus 로고
    • Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients
    • Bow EJ. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Med Mycol 2005; 43 (suppl 1): S277-S287.
    • (2005) Med Mycol , vol.43 , Issue.SUPPL. 1
    • Bow, E.J.1
  • 16
    • 20144388435 scopus 로고    scopus 로고
    • Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003
    • Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
    • (2005) J Clin Microbiol , vol.43 , pp. 1829-1835
    • Almirante, B.1    Rodriguez, D.2    Park, B.J.3
  • 17
    • 34248160575 scopus 로고    scopus 로고
    • Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
    • Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
    • (2007) Clin Infect Dis , vol.44 , pp. 1289-1297
    • Cornely, O.A.1    Maertens, J.2    Bresnik, M.3
  • 18
    • 33747616462 scopus 로고    scopus 로고
    • Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey
    • Cornillet A, Camus C, Nimubona S et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577-584.
    • (2006) Clin Infect Dis , vol.43 , pp. 577-584
    • Cornillet, A.1    Camus, C.2    Nimubona, S.3
  • 19
    • 30844436593 scopus 로고    scopus 로고
    • Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000-2002)
    • Fourneret-Vivier A, Lebeau B, Mallaret MR et al. Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000-2002). J Hosp Infect 2006; 62: 22-28.
    • (2006) J Hosp Infect , vol.62 , pp. 22-28
    • Fourneret-Vivier, A.1    Lebeau, B.2    Mallaret, M.R.3
  • 20
    • 0037043655 scopus 로고    scopus 로고
    • Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    • Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
    • (2002) N Engl J Med , vol.347 , pp. 408-415
    • Herbrecht, R.1    Denning, D.W.2    Patterson, T.F.3
  • 21
    • 28444468369 scopus 로고    scopus 로고
    • Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience
    • Lass-Florl C, Griff K, Mayr A et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-207.
    • (2005) Br J Haematol , vol.131 , pp. 201-207
    • Lass-Florl, C.1    Griff, K.2    Mayr, A.3
  • 22
    • 33747055130 scopus 로고    scopus 로고
    • The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study
    • Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-1075.
    • (2006) Haematologica , vol.91 , pp. 1068-1075
    • Pagano, L.1    Caira, M.2    Candoni, A.3
  • 23
    • 77950682818 scopus 로고    scopus 로고
    • Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study
    • Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644-650.
    • (2010) Haematologica , vol.95 , pp. 644-650
    • Pagano, L.1    Caira, M.2    Candoni, A.3
  • 25
    • 70249140598 scopus 로고    scopus 로고
    • Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation
    • Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009; 27: 3398-3409.
    • (2009) J Clin Oncol , vol.27 , pp. 3398-3409
    • Michallet, M.1    Ito, J.I.2
  • 26
    • 71449090672 scopus 로고    scopus 로고
    • Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients
    • Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 2009; 168: 299-311.
    • (2009) Mycopathologia , vol.168 , pp. 299-311
    • Wirk, B.1    Wingard, J.R.2
  • 27
    • 67651125197 scopus 로고    scopus 로고
    • Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation
    • Chandrasekar P. Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation. Med Mycol 2009; 47 (suppl 1): S349-S354.
    • (2009) Med Mycol , vol.47 , Issue.SUPPL. 1
    • Chandrasekar, P.1
  • 28
    • 49049100517 scopus 로고    scopus 로고
    • Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies
    • Marr KA. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Curr Opin Infect Dis 2008; 21: 409-414.
    • (2008) Curr Opin Infect Dis , vol.21 , pp. 409-414
    • Marr, K.A.1
  • 29
    • 51449113448 scopus 로고    scopus 로고
    • Patients at high risk of invasive fungal infections: when and how to treat
    • Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008; 68: 1941-1962.
    • (2008) Drugs , vol.68 , pp. 1941-1962
    • Ruping, M.J.1    Vehreschild, J.J.2    Cornely, O.A.3
  • 30
    • 74949125913 scopus 로고    scopus 로고
    • Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome - still an open question?
    • Ruping MJ, Vehreschild JJ, Cornely OA. Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome - still an open question? Leuk Lymphoma 2010; 51: 20-26.
    • (2010) Leuk Lymphoma , vol.51 , pp. 20-26
    • Ruping, M.J.1    Vehreschild, J.J.2    Cornely, O.A.3
  • 31
    • 33846462456 scopus 로고    scopus 로고
    • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
    • Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
    • (2007) N Engl J Med , vol.356 , pp. 348-359
    • Cornely, O.A.1    Maertens, J.2    Winston, D.J.3
  • 32
    • 84860390037 scopus 로고    scopus 로고
    • Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic stem cell transplanation
    • Marks DI, Pagliuca A, Kibbler CC et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic stem cell transplanation. Br J Haematol 2011; 155: 318-327.
    • (2011) Br J Haematol , vol.155 , pp. 318-327
    • Marks, D.I.1    Pagliuca, A.2    Kibbler, C.C.3
  • 33
    • 8744314133 scopus 로고    scopus 로고
    • Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation
    • van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416.
    • (2004) Clin Infect Dis , vol.39 , pp. 1407-1416
    • van Burik, J.A.1    Ratanatharathorn, V.2    Stepan, D.E.3
  • 34
    • 78650058029 scopus 로고    scopus 로고
    • Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
    • Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-5118.
    • (2010) Blood , vol.116 , pp. 5111-5118
    • Wingard, J.R.1    Carter, S.L.2    Walsh, T.J.3
  • 35
    • 70449478487 scopus 로고    scopus 로고
    • Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation
    • Wolf J, Slavin MA. Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation. Curr Infect Dis Rep 2009; 11: 420-426.
    • (2009) Curr Infect Dis Rep , vol.11 , pp. 420-426
    • Wolf, J.1    Slavin, M.A.2
  • 36
    • 84866454916 scopus 로고    scopus 로고
    • The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections
    • Maschmeyer G. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections. J Antimicrob Chemother 2009; 63 (suppl 1): i27-i30.
    • (2009) J Antimicrob Chemother , vol.63 , Issue.SUPPL. 1
    • Maschmeyer, G.1
  • 37
    • 51349159745 scopus 로고    scopus 로고
    • Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients
    • Tamura K, Drew R. Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients. Drugs Today (Barc) 2008; 44: 515-530.
    • (2008) Drugs Today (Barc) , vol.44 , pp. 515-530
    • Tamura, K.1    Drew, R.2
  • 38
    • 70149115067 scopus 로고    scopus 로고
    • A new step toward individualized antifungal prevention in hematopoietic stem cell transplantation
    • Bochud PY, Calandra T. A new step toward individualized antifungal prevention in hematopoietic stem cell transplantation. Clin Infect Dis 2009; 49: 733-735.
    • (2009) Clin Infect Dis , vol.49 , pp. 733-735
    • Bochud, P.Y.1    Calandra, T.2
  • 39
    • 33846439749 scopus 로고    scopus 로고
    • Prophylaxis and aspergillosis - has the principle been proven?
    • De PB, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356: 409-411.
    • (2007) N Engl J Med , vol.356 , pp. 409-411
    • De, P.B.1    Donnelly, J.P.2
  • 40
    • 0842307309 scopus 로고    scopus 로고
    • Cyclophosphamide metabolism is affected by azole antifungals
    • Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-1559.
    • (2004) Blood , vol.103 , pp. 1557-1559
    • Marr, K.A.1    Leisenring, W.2    Crippa, F.3
  • 41
    • 33745755772 scopus 로고    scopus 로고
    • A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients
    • Oren I, Rowe JM, Sprecher H et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006; 38: 127-134.
    • (2006) Bone Marrow Transplant , vol.38 , pp. 127-134
    • Oren, I.1    Rowe, J.M.2    Sprecher, H.3
  • 42
    • 42549085783 scopus 로고    scopus 로고
    • Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial
    • Rijnders BJ, Cornelissen JJ, Slobbe L et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401-1408.
    • (2008) Clin Infect Dis , vol.46 , pp. 1401-1408
    • Rijnders, B.J.1    Cornelissen, J.J.2    Slobbe, L.3
  • 43
    • 33744495089 scopus 로고    scopus 로고
    • In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts
    • Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 2009-2015
    • Sabatelli, F.1    Patel, R.2    Mann, P.A.3
  • 44
    • 0028997086 scopus 로고
    • Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study
    • Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
    • (1995) J Infect Dis , vol.171 , pp. 1545-1552
    • Slavin, M.A.1    Osborne, B.2    Adams, R.3
  • 45
    • 0036233027 scopus 로고    scopus 로고
    • In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes
    • Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-1582.
    • (2002) Antimicrob Agents Chemother , vol.46 , pp. 1581-1582
    • Sun, Q.N.1    Fothergill, A.W.2    McCarthy, D.I.3    Rinaldi, M.G.4    Graybill, J.R.5
  • 46
    • 33846410666 scopus 로고    scopus 로고
    • Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
    • Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
    • (2007) N Engl J Med , vol.356 , pp. 335-347
    • Ullmann, A.J.1    Lipton, J.H.2    Vesole, D.H.3
  • 47
    • 0037736664 scopus 로고    scopus 로고
    • Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter randomized trial
    • Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter randomized trial. Ann Intern Med 2003; 138: 705-713.
    • (2003) Ann Intern Med , vol.138 , pp. 705-713
    • Winston, D.J.1    Maziarz, R.T.2    Chandrasekar, P.H.3
  • 49
    • 84862813791 scopus 로고    scopus 로고
    • Pfizer, Inc. New York, NY: Pfizer, Inc.
    • Pfizer, Inc. Vfend [US prescribing information]. New York, NY: Pfizer, Inc., 2011.
    • (2011) Vfend [US prescribing information]
  • 50
    • 84866029048 scopus 로고    scopus 로고
    • European Medicines Agency. European Medicines Agency, Available at: (accessed on 7 September 2011).
    • European Medicines Agency. Vfend-product information. European Medicines Agency, Available at: (accessed on 7 September 2011).
    • Vfend-product information
  • 51
    • 77953381993 scopus 로고    scopus 로고
    • Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections
    • Cecil JA, Wenzel RP. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Expert Rev Hematol 2009; 2: 237-254.
    • (2009) Expert Rev Hematol , vol.2 , pp. 237-254
    • Cecil, J.A.1    Wenzel, R.P.2
  • 52
    • 26944446579 scopus 로고    scopus 로고
    • Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
    • Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442.
    • (2005) Lancet , vol.366 , pp. 1435-1442
    • Kullberg, B.J.1    Sobel, J.D.2    Ruhnke, M.3
  • 53
    • 0038556830 scopus 로고    scopus 로고
    • Voriconazole treatment for less-common, emerging, or refractory fungal infections
    • Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
    • (2003) Clin Infect Dis , vol.36 , pp. 1122-1131
    • Perfect, J.R.1    Marr, K.A.2    Walsh, T.J.3
  • 54
    • 42949088904 scopus 로고    scopus 로고
    • Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients
    • Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743-1750.
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 1743-1750
    • Troke, P.1    Aguirrebengoa, K.2    Arteaga, C.3
  • 55
    • 0036191021 scopus 로고    scopus 로고
    • Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
    • Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248.
    • (2002) Pediatr Infect Dis J , vol.21 , pp. 240-248
    • Walsh, T.J.1    Lutsar, I.2    Driscoll, T.3
  • 56
    • 79955898005 scopus 로고    scopus 로고
    • European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 - 2009 update
    • Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 - 2009 update. Bone Marrow Transplant 2011; 46: 709-718.
    • (2011) Bone Marrow Transplant , vol.46 , pp. 709-718
    • Maertens, J.1    Marchetti, O.2    Herbrecht, R.3
  • 57
    • 85031185125 scopus 로고    scopus 로고
    • Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. BCSH Guidelines Home Page. (accessed on 7 September 2011).
    • Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. BCSH Guidelines Home Page. (accessed on 7 September 2011).
  • 58
    • 46149088713 scopus 로고    scopus 로고
    • Recommendations for the treatment of established fungal infections
    • Thursky KA, Playford EG, Seymour JF et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008; 38: 496-520.
    • (2008) Intern Med J , vol.38 , pp. 496-520
    • Thursky, K.A.1    Playford, E.G.2    Seymour, J.F.3
  • 59
    • 39449095735 scopus 로고    scopus 로고
    • Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
    • Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
    • (2008) Clin Infect Dis , vol.46 , pp. 327-360
    • Walsh, T.J.1    Anaissie, E.J.2    Denning, D.W.3
  • 60
    • 58149088852 scopus 로고    scopus 로고
    • Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    • Bohme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
    • (2009) Ann Hematol , vol.88 , pp. 97-110
    • Bohme, A.1    Ruhnke, M.2    Buchheidt, D.3
  • 61
    • 78650530503 scopus 로고    scopus 로고
    • Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease
    • Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother 2011; 66 (suppl 1): i25-i35.
    • (2011) J Antimicrob Chemother , vol.66 , Issue.SUPPL. 1
    • Freemantle, N.1    Tharmanathan, P.2    Herbrecht, R.3
  • 62
    • 33646458665 scopus 로고    scopus 로고
    • Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen
    • Capitano B, Potoski BA, Husain S et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006; 50: 1878-1880.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 1878-1880
    • Capitano, B.1    Potoski, B.A.2    Husain, S.3
  • 64
    • 71649092227 scopus 로고    scopus 로고
    • Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole
    • Cowen EW, Nguyen JC, Miller DD et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62: 31-37.
    • (2010) J Am Acad Dermatol , vol.62 , pp. 31-37
    • Cowen, E.W.1    Nguyen, J.C.2    Miller, D.D.3
  • 65
    • 77949373240 scopus 로고    scopus 로고
    • Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity
    • Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146: 300-304.
    • (2010) Arch Dermatol , vol.146 , pp. 300-304
    • Miller, D.D.1    Cowen, E.W.2    Nguyen, J.C.3    McCalmont, T.H.4    Fox, L.P.5
  • 66
    • 40549102818 scopus 로고    scopus 로고
    • Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity
    • Whittle AM, Ali S. Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity. Int J Lab Hematol 2008; 30: 173-174.
    • (2008) Int J Lab Hematol , vol.30 , pp. 173-174
    • Whittle, A.M.1    Ali, S.2
  • 67
    • 34247147624 scopus 로고    scopus 로고
    • Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
    • Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-1535.
    • (2007) Cancer , vol.109 , pp. 1532-1535
    • Trifilio, S.1    Pennick, G.2    Pi, J.3
  • 68
    • 34548062677 scopus 로고    scopus 로고
    • Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole
    • Trifilio S, Singhal S, Williams S et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40: 451-456.
    • (2007) Bone Marrow Transplant , vol.40 , pp. 451-456
    • Trifilio, S.1    Singhal, S.2    Williams, S.3
  • 70
    • 39449117139 scopus 로고    scopus 로고
    • Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
    • Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
    • (2008) Clin Infect Dis , vol.46 , pp. 201-211
    • Pascual, A.1    Calandra, T.2    Bolay, S.3    Buclin, T.4    Bille, J.5    Marchetti, O.6
  • 71
    • 31344478761 scopus 로고    scopus 로고
    • Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
    • Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235-243.
    • (2006) J Clin Pharmacol , vol.46 , pp. 235-243
    • Tan, K.1    Brayshaw, N.2    Tomaszewski, K.3    Troke, P.4    Wood, N.5
  • 73
    • 71249114710 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults
    • Lebeaux D, Lanternier F, Elie C et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53: 5224-5229.
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 5224-5229
    • Lebeaux, D.1    Lanternier, F.2    Elie, C.3
  • 74
    • 70349980689 scopus 로고    scopus 로고
    • Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
    • Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15 (suppl 5): 93-97.
    • (2009) Clin Microbiol Infect , vol.15 , Issue.SUPPL. 5 , pp. 93-97
    • Pongas, G.N.1    Lewis, R.E.2    Samonis, G.3    Kontoyiannis, D.P.4
  • 75
    • 0026597735 scopus 로고
    • A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
    • Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
    • (1992) N Engl J Med , vol.326 , pp. 845-851
    • Goodman, J.L.1    Winston, D.J.2    Greenfield, R.A.3
  • 76
    • 33747892111 scopus 로고    scopus 로고
    • Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial
    • Penack O, Schwartz S, Martus P et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17: 1306-1312.
    • (2006) Ann Oncol , vol.17 , pp. 1306-1312
    • Penack, O.1    Schwartz, S.2    Martus, P.3
  • 77
    • 31544444209 scopus 로고    scopus 로고
    • An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia
    • Glasmacher A, Cornely O, Ullmann AJ et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57: 317-325.
    • (2006) J Antimicrob Chemother , vol.57 , pp. 317-325
    • Glasmacher, A.1    Cornely, O.2    Ullmann, A.J.3
  • 78
    • 0842328814 scopus 로고    scopus 로고
    • Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
    • Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
    • (2004) Blood , vol.103 , pp. 1527-1533
    • Marr, K.A.1    Crippa, F.2    Leisenring, W.3
  • 79
    • 85031183269 scopus 로고    scopus 로고
    • Response to: voriconazole prophylaxis and the risk of invasive fungal infection after allogeneic HCT. [eLetter]. (accessed on 8 February 2012).
    • Wingard JR, Baden LR, Kurtzberg J et al. Response to: voriconazole prophylaxis and the risk of invasive fungal infection after allogeneic HCT. [eLetter]. (accessed on 8 February 2012).
    • Wingard, J.R.1    Baden, L.R.2    Kurtzberg, J.3
  • 80
    • 85031182151 scopus 로고    scopus 로고
    • Voriconazole prophylaxis and the risk of invasive fungal infection after allogeneic HCT. [eLetter]. (accessed on 8 February 2012).
    • Girmenia C, Aversa F, Micozzi A et al. Voriconazole prophylaxis and the risk of invasive fungal infection after allogeneic HCT. [eLetter]. (accessed on 8 February 2012).
    • Girmenia, C.1    Aversa, F.2    Micozzi, A.3
  • 81
    • 77957571776 scopus 로고    scopus 로고
    • Voriconazole or itraconazole for antifungal prophylaxis in patients with grade II-IV acute or extensive chronic graft-versus-host disease
    • Abstract 1253.
    • Marks D, Kibbler C, Cook G et al. Voriconazole or itraconazole for antifungal prophylaxis in patients with grade II-IV acute or extensive chronic graft-versus-host disease. Bone Marrow Transplant 2010; 45: S78-S327, Abstract 1253.
    • (2010) Bone Marrow Transplant , vol.45
    • Marks, D.1    Kibbler, C.2    Cook, G.3
  • 82
    • 53349157204 scopus 로고    scopus 로고
    • Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation
    • Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
    • (2008) Clin Infect Dis , vol.47 , pp. 1041-1050
    • Garcia-Vidal, C.1    Upton, A.2    Kirby, K.A.3    Marr, K.A.4
  • 83
    • 77953194474 scopus 로고    scopus 로고
    • Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia
    • Chabrol A, Cuzin L, Huguet F et al. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica 2010; 95: 996-1003.
    • (2010) Haematologica , vol.95 , pp. 996-1003
    • Chabrol, A.1    Cuzin, L.2    Huguet, F.3
  • 84
    • 77950629027 scopus 로고    scopus 로고
    • Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD
    • Gergis U, Markey K, Greene J et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant 2010; 45: 662-667.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 662-667
    • Gergis, U.1    Markey, K.2    Greene, J.3
  • 85
    • 77149122731 scopus 로고    scopus 로고
    • Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation
    • Martin T, Sharma M, Damon L et al. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2010; 12: 45-50.
    • (2010) Transpl Infect Dis , vol.12 , pp. 45-50
    • Martin, T.1    Sharma, M.2    Damon, L.3
  • 86
    • 33745258668 scopus 로고    scopus 로고
    • Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis
    • Siwek GT, Pfaller MA, Polgreen PM et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55: 209-212.
    • (2006) Diagn Microbiol Infect Dis , vol.55 , pp. 209-212
    • Siwek, G.T.1    Pfaller, M.A.2    Polgreen, P.M.3
  • 87
    • 76249128351 scopus 로고    scopus 로고
    • Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia
    • Torres A, Serrano J, Rojas R et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol 2010; 84: 271-273.
    • (2010) Eur J Haematol , vol.84 , pp. 271-273
    • Torres, A.1    Serrano, J.2    Rojas, R.3
  • 88
    • 35448957762 scopus 로고    scopus 로고
    • A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML)
    • Vehreschild JJ, Bohme A, Buchheidt D et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007; 55: 445-449.
    • (2007) J Infect , vol.55 , pp. 445-449
    • Vehreschild, J.J.1    Bohme, A.2    Buchheidt, D.3
  • 89
    • 57149096710 scopus 로고    scopus 로고
    • Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia
    • Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008; 65: 2237-2243.
    • (2008) Am J Health Syst Pharm , vol.65 , pp. 2237-2243
    • Collins, C.D.1    Ellis, J.J.2    Kaul, D.R.3
  • 90
    • 77952423334 scopus 로고    scopus 로고
    • Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT
    • de la Camara R, Jarque I, Sanz MA et al. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant 2010; 45: 925-932.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 925-932
    • de la Camara, R.1    Jarque, I.2    Sanz, M.A.3
  • 91
    • 37549013676 scopus 로고    scopus 로고
    • Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections
    • de Vries R, Daenen S, Tolley K et al. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics 2008; 26: 75-90.
    • (2008) Pharmacoeconomics , vol.26 , pp. 75-90
    • de Vries, R.1    Daenen, S.2    Tolley, K.3
  • 92
    • 56649109482 scopus 로고    scopus 로고
    • Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands
    • Stam WB, O'Sullivan AK, Rijnders B et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008; 81: 467-474.
    • (2008) Eur J Haematol , vol.81 , pp. 467-474
    • Stam, W.B.1    O'Sullivan, A.K.2    Rijnders, B.3
  • 93
    • 77956489402 scopus 로고    scopus 로고
    • Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study
    • Cordonnier C, Rovira M, Maertens J et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762-1768.
    • (2010) Haematologica , vol.95 , pp. 1762-1768
    • Cordonnier, C.1    Rovira, M.2    Maertens, J.3
  • 94
    • 2942693867 scopus 로고    scopus 로고
    • Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center
    • Fukuda T, Boeckh M, Guthrie KA et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494-503.
    • (2004) Biol Blood Marrow Transplant , vol.10 , pp. 494-503
    • Fukuda, T.1    Boeckh, M.2    Guthrie, K.A.3
  • 95
    • 33750515267 scopus 로고    scopus 로고
    • Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
    • Martino R, Parody R, Fukuda T et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-2936.
    • (2006) Blood , vol.108 , pp. 2928-2936
    • Martino, R.1    Parody, R.2    Fukuda, T.3
  • 96
    • 0031950358 scopus 로고    scopus 로고
    • Impact of previous aspergillosis on the outcome of bone marrow transplantation
    • Offner F, Cordonnier C, Ljungman P et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098-1103.
    • (1998) Clin Infect Dis , vol.26 , pp. 1098-1103
    • Offner, F.1    Cordonnier, C.2    Ljungman, P.3
  • 97
    • 0028224382 scopus 로고
    • Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy
    • Cowie F, Meller ST, Cushing P, Pinkerton R. Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy. Arch Dis Child 1994; 70: 136-138.
    • (1994) Arch Dis Child , vol.70 , pp. 136-138
    • Cowie, F.1    Meller, S.T.2    Cushing, P.3    Pinkerton, R.4
  • 98
    • 2442670429 scopus 로고    scopus 로고
    • Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients
    • Cordonnier C, Maury S, Pautas C et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-948.
    • (2004) Bone Marrow Transplant , vol.33 , pp. 943-948
    • Cordonnier, C.1    Maury, S.2    Pautas, C.3
  • 99
    • 80051776285 scopus 로고    scopus 로고
    • Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature
    • Masamoto Y, Nannya Y, Kurokawa M. Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature. J Chemother 2011; 23: 17-23.
    • (2011) J Chemother , vol.23 , pp. 17-23
    • Masamoto, Y.1    Nannya, Y.2    Kurokawa, M.3
  • 100
    • 64949114058 scopus 로고    scopus 로고
    • Hematopoietic SCT in patients with a history of invasive fungal infection
    • Zhang P, Song A, Wang Z, Feng S, Qiu L, Han M. Hematopoietic SCT in patients with a history of invasive fungal infection. Bone Marrow Transplant 2009; 43: 533-537.
    • (2009) Bone Marrow Transplant , vol.43 , pp. 533-537
    • Zhang, P.1    Song, A.2    Wang, Z.3    Feng, S.4    Qiu, L.5    Han, M.6
  • 101
    • 85031192496 scopus 로고    scopus 로고
    • Effective secondary antifungal prophylaxis with voriconazole. Presented at: European Hematology Association; June 12-15, 2008; Copenhagen, Denmark. Abstract 0183
    • Dignan F, Grigoriadou V, Maxwell F et al. Effective secondary antifungal prophylaxis with voriconazole. Presented at: European Hematology Association; June 12-15, 2008; Copenhagen, Denmark. Abstract 0183.
    • Dignan, F.1    Grigoriadou, V.2    Maxwell, F.3
  • 102
    • 34547211213 scopus 로고    scopus 로고
    • Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection
    • de Fabritiis P, Spagnoli A, Di BP et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007; 40: 245-249.
    • (2007) Bone Marrow Transplant , vol.40 , pp. 245-249
    • de Fabritiis, P.1    Spagnoli, A.2    Di, B.P.3
  • 103
    • 17144431416 scopus 로고    scopus 로고
    • Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B
    • Kruger WH, Russmann B, de WM et al. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005; 113: 104-108.
    • (2005) Acta Haematol , vol.113 , pp. 104-108
    • Kruger, W.H.1    Russmann, B.2    de, W.M.3
  • 105
    • 60549098868 scopus 로고    scopus 로고
    • Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
    • Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
    • (2009) Clin Infect Dis , vol.48 , pp. 503-535
    • Pappas, P.G.1    Kauffman, C.A.2    Andes, D.3
  • 106
    • 70350787236 scopus 로고    scopus 로고
    • Fungal infection prevention after hematopoietic cell transplantation
    • Marr KA, Bow E, Chiller T et al. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44: 483-487.
    • (2009) Bone Marrow Transplant , vol.44 , pp. 483-487
    • Marr, K.A.1    Bow, E.2    Chiller, T.3
  • 107
    • 69849102119 scopus 로고    scopus 로고
    • Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective
    • Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238.
    • (2009) Biol Blood Marrow Transplant , vol.15 , pp. 1143-1238
    • Tomblyn, M.1    Chiller, T.2    Einsele, H.3
  • 108
    • 58149234268 scopus 로고    scopus 로고
    • Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology
    • Cornely OA, Bohme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113-122.
    • (2009) Haematologica , vol.94 , pp. 113-122
    • Cornely, O.A.1    Bohme, A.2    Buchheidt, D.3
  • 109
    • 77950255105 scopus 로고    scopus 로고
    • Forty-one recent cases of invasive zygomycosis from a global clinical registry
    • Ruping MJ, Heinz WJ, Kindo AJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65: 296-302.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 296-302
    • Ruping, M.J.1    Heinz, W.J.2    Kindo, A.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.